Genmab A/S
GMAB
ISIN null / Valor 21487099
Genmab A/S
UMushroom community rating:
About company
Genmab A/S is a Copenhagen‑based biotechnology company that discovers and develops antibody therapeutics, with a particular focus on oncology. The company uses proprietary platforms such as DuoBody (bispecific antibodies) and HexaBody (Fc‑engineered antibodies) to generate differentiated monoclonal and multispecific candidates and advances a pipeline of programs through preclinical and clinical stages. Genmab’s business model combines in‑house research with partnering agreements with larger pharmaceutical companies for late‑stage development and commercialization, generating revenue from milestone payments, royalties and, in some cases, co‑commercialization arrangements; a notable commercial success from such collaborations is daratumumab (marketed as DARZALEX by Janssen) for multiple myeloma. Genmab is publicly listed and focuses R&D investment on advancing its antibody platforms and clinical programs toward regulatory approval and commercial uptake.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
15622 M
Market cap (USD)
1,711,254
Daily traded volume (Shares)
20.87 / 20.69
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
